Literature DB >> 31187560

Radiomics nomogram based on MRI for predicting white matter hyperintensity progression in elderly adults.

Zhen-Yu Shu1, Yuan Shao1, Yu-Yun Xu1, Qin Ye1,2, Si-Jia Cui1,2, De-Wang Mao1, Pei-Pei Pang3, Xiang-Yang Gong1,4.   

Abstract

BACKGROUND: White matter hyperintensity (WMH) is widely observed in aging brain and is associated with various diseases. A pragmatic and handy method in the clinic to assess and follow up white matter disease is strongly in need.
PURPOSE: To develop and validate a radiomics nomogram for the prediction of WMH progression. STUDY TYPE: Retrospective. POPULATION: Brain images of 193 WMH patients from the Picture Archiving and Communication Systems (PACS) database in the A Medical Center (Zhejiang Provincial People's Hospital). MRI data of 127 WMH patients from the PACS database in the B Medical Center (Zhejiang Lishui People's Hospital) were included for external validation. All of the patients were at least 60 years old. FIELD STRENGTH/SEQUENCE: T1 -fluid attenuated inversion recovery images were acquired using a 3T scanner. ASSESSMENT: WMH was evaluated utilizing the Fazekas scale based on MRI. WMH progression was assessed with a follow-up MRI using a visual rating scale. Three neuroradiologists, who were blinded to the clinical data, assessed the images independently. Moreover, interobserver and intraobserver reproducibility were performed for the regions of interest for segmentation and feature extraction. STATISTICAL TESTS: A receiver operating characteristic (ROC) curve, the area under the curve (AUC) of the ROC was calculated, along with sensitivity and specificity. Also, a Hosmer-Lemeshow test was performed.
RESULTS: The AUC of radiomics signature in the primary, internal validation cohort, external validation cohort were 0.886, 0.816, and 0.787, respectively; the specificity were 71.79%, 72.22%, and 81%, respectively; the sensitivity were 92.68%, 87.94% and 78.3%, respectively. The radiomics nomogram in the primary cohort (AUC = 0.899) and the internal validation cohort (AUC = 0.84). The Hosmer-Lemeshow test showed no significant difference between the primary cohort and the internal validation cohort (P > 0.05). The AUC of the radiomics nomogram, radiomics signature, and hyperlipidemia in all patients from the primary and internal validation cohort was 0.878, 0.848, and 0.626, respectively. DATA
CONCLUSION: This multicenter study demonstrated the use of a radiomics nomogram in predicting the progression of WMH with elderly adults (an age of at least 60 years) based on conventional MRI. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2020;51:535-546.
© 2019 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  magnetic resonance imaging; nomogram; progression; radiomics; white matter hyperintensity

Mesh:

Year:  2019        PMID: 31187560     DOI: 10.1002/jmri.26813

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  7 in total

1.  Development of a PET/CT molecular radiomics-clinical model to predict thoracic lymph node metastasis of invasive lung adenocarcinoma ≤ 3 cm in diameter.

Authors:  Cheng Chang; Maomei Ruan; Bei Lei; Jian Feng; Wenhui Xie; Hong Yu; Wenlu Zhao; Yaqiong Ge; Shaofeng Duan; Wenjing Teng; Qianfu Wu; Xiaohua Qian; Lihua Wang; Hui Yan; Ciyi Liu; Liu Liu
Journal:  EJNMMI Res       Date:  2022-04-21       Impact factor: 3.434

2.  Parkinson's Disease Diagnosis Using Neostriatum Radiomic Features Based on T2-Weighted Magnetic Resonance Imaging.

Authors:  Panshi Liu; Han Wang; Shilei Zheng; Fan Zhang; Xianglin Zhang
Journal:  Front Neurol       Date:  2020-04-08       Impact factor: 4.003

3.  Comparing the Performance of Two Radiomic Models to Predict Progression and Progression Speed of White Matter Hyperintensities.

Authors:  Yuan Shao; Jingru Ruan; Yuyun Xu; Zhenyu Shu; Xiaodong He
Journal:  Front Neuroinform       Date:  2021-12-01       Impact factor: 4.081

4.  Can computed tomography-based radiomics potentially discriminate between anterior mediastinal cysts and type B1 and B2 thymomas?

Authors:  Lulu Liu; Fangxiao Lu; Peipei Pang; Guoliang Shao
Journal:  Biomed Eng Online       Date:  2020-11-27       Impact factor: 2.819

5.  Radiation-induced occult insufficiency fracture or bone metastasis after radiotherapy for cervical cancer? The nomogram based on quantitative apparent diffusion coefficients for discrimination.

Authors:  Xi Zhong; Huali Jiang; Hui Mai; Jialin Xiang; Jiansheng Li; Zhiqing Huang; Songxin Wu; Liangping Luo; Kuiming Jiang
Journal:  Cancer Imaging       Date:  2020-10-23       Impact factor: 3.909

6.  Prediction of the progression from mild cognitive impairment to Alzheimer's disease using a radiomics-integrated model.

Authors:  Zhen-Yu Shu; De-Wang Mao; Yu-Yun Xu; Yuan Shao; Pei-Pei Pang; Xiang-Yang Gong
Journal:  Ther Adv Neurol Disord       Date:  2021-07-15       Impact factor: 6.570

7.  MRI Radiomic Signature of White Matter Hyperintensities Is Associated With Clinical Phenotypes.

Authors:  Martin Bretzner; Anna K Bonkhoff; Markus D Schirmer; Sungmin Hong; Adrian V Dalca; Kathleen L Donahue; Anne-Katrin Giese; Mark R Etherton; Pamela M Rist; Marco Nardin; Razvan Marinescu; Clinton Wang; Robert W Regenhardt; Xavier Leclerc; Renaud Lopes; Oscar R Benavente; John W Cole; Amanda Donatti; Christoph J Griessenauer; Laura Heitsch; Lukas Holmegaard; Katarina Jood; Jordi Jimenez-Conde; Steven J Kittner; Robin Lemmens; Christopher R Levi; Patrick F McArdle; Caitrin W McDonough; James F Meschia; Chia-Ling Phuah; Arndt Rolfs; Stefan Ropele; Jonathan Rosand; Jaume Roquer; Tatjana Rundek; Ralph L Sacco; Reinhold Schmidt; Pankaj Sharma; Agnieszka Slowik; Alessandro Sousa; Tara M Stanne; Daniel Strbian; Turgut Tatlisumak; Vincent Thijs; Achala Vagal; Johan Wasselius; Daniel Woo; Ona Wu; Ramin Zand; Bradford B Worrall; Jane M Maguire; Arne Lindgren; Christina Jern; Polina Golland; Grégory Kuchcinski; Natalia S Rost
Journal:  Front Neurosci       Date:  2021-07-12       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.